Loading
A phase 2/3 trial of Piflufolastat F-18 / Pylarify TruVu in Prostate cancer, run by Progenics Pharmaceuticals, Inc., completed.
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer is a phase 2/3 interventional study registered as NCT02981368 by Progenics Pharmaceuticals, Inc., with 385 participants recorded, started 2016-11 and reaching its primary completion in 2018-07. Interventions recorded: 18F-DCFPyL Injection, PET/CT imaging. Conditions recorded: Prostate Cancer.
Linked to the drug Piflufolastat F-18 / Pylarify TruVu because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Piflufolastat F-18 / Pylarify TruVu, Lantheus, Prostate cancer and the tag pipeline.
Shares Piflufolastat F-18 / Pylarify TruVu, Prostate cancer and the tag pipeline.
Shares Lantheus and the tag pipeline.
Shares Lantheus and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/